Vertical: HealthcareBase Year: 2021
Market Size (2021)
$1.59B
Projected (2030)
$2.73B
CAGR (2018–2030)
5.8%
Key Players
10+
The global PEG 3350 market is growing as a result of factors such as the rising prevalence of colon cancer in India, the rising number of strategic initiatives, and increasing sedentary lifestyles and physical inactivity. Furthermore, entering developing markets further creates lucrative growth opportunities. However, side effects associated with PEG 3500 and an increasing preference for alternatives are impeding the market's growth.
The PEG 3350 Market market is projected to grow at a CAGR of 5.8% from 2018 to 2030.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansPolyethylene glycol 3350 is in a class of medications called osmotic laxatives. Its main role is to cause water to be retained in the stool. This increases the number of bowel movements and softens the stool, making it easier to pass. It is commonly used to treat constipation, before medical tests of the colon and rectum, before colorectal surgery, and after surgery to alleviate constipation.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2021
Historical Period
2018 – 2020
Forecast Period
2022 – 2030
Primary Interviews
150+
Historical data (2018–2021) and forecast period (2021–2030)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe COVID-19 pandemic situation has resulted in many restrictions around the world, still, the players manufacturing PEG 3350 products were able to manage their product stock. Further, governing bodies of respective nations made significant efforts to aid in the proper distribution and supple of healthcare goods. Government and private companies around the world were working together to issue advice for those undergoing constipation treatment during these unprecedented times of COVID-19 around the world. Several steps were taken to get their needed output for the product. Additionally, by increasing the material prices, the companies attempted in maintaining their overall revenue. Hence, companies in the PEG 3350 market are finding out their ways to deal with this pandemic situation.
With respect to the current scope of the report, McKesson Corporation (US) is the top player in the global PEG 3350 market due to its strong product offering and high preference for its products by customers. Bayer AG (Germany) is the second major player, followed by BASF SE (Germany), Merck KGaA (US), and Teva Pharmaceutical Industries Ltd. (Israel). Other key players contributing to the market growth include Lupin Pharmaceuticals, Inc. (India), Breckenridge Pharmaceutical, Inc. (US), Pendopharm (Canada), LGM Pharma (US), and Sisco Research Laboratories Pvt. Ltd. (India).
Threat of New Entrants
The threat of new entrants in the global PEG 3350 market is moderate. The global PEG 3350 market is steadily growing, hence attracting many new entrants who are looking to make a profit. However, the entry barriers are high due to strict government norms and regulations which decreases the threat of new entrants to some level. Companies aim to increase their market share and capture the market share which is mostly untouched by major players. Hence, the threat of new entrants in the global PEG 3350 market is moderate.
Bargaining Power of Suppliers
The bargaining power of suppliers in the global PEG 3350 market is high as there is an increase in demand for raw materials by pharmaceutical companies. However, the number of suppliers is also high in the market, which is slightly decreasing the bargaining power of suppliers, as switching cost is low. Additionally, the supply of raw materials is disrupted to some level due to the logistics issues that the world is facing currently, which in turn increases the bargaining power of suppliers.
Threat of Substitutes
The threat of substitutes in the PEG 3350 market is high. There are many substitutes for PEG 3350 such as magnesium citrate supplement and presence of natural alternatives. The doctors tend to prescribe the type of treatment that is suitable for the patient and also affordable.
Bargaining Power of Buyers
The bargaining power of buyers is moderate in the global PEG 3350 market. Online pharmacies and offline pharmacies are the major buyers in the market. The bargaining power of the buyer can define how easily the buyer can get the products. Buyers in the global PEG 3350 market can choose from different companies. Most of the companies are offering the same kind of products so the switching cost for the buyer is relatively low.
Intensity of Rivalry
The degree of competition in the PEG 3350 market is high owing to the presence of a large number of prominent players. Low level of product differentiation among existing players increases the intensity of rivalry in the market. Polyethylene glycol 3350 companies are trying to develop economical and more effective medications to make the treatment more affordable and attractive. Additionally, the providers are also involved in innovating medicines for the different routes of administration. Such innovations might increase the level of product differentiation and will support the sales of the manufacturers.
Market estimates by geography (2030)
InsightNorth America leads with $1.15B by 2030, while Asia Pacific is projected to grow fastest at a 7.6% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2018 | 2021 | 2030 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $566.24M | $770.97M | $1.15B | 6.1% | 42% |
| Europe | $377.55M | $493.86M | $706.19M | 5.4% | 26% |
| Asia Pacific | $243.52M | $361.85M | $583.30M | 7.6% | 21% |
| Rest of the World | $205.71M | $238.35M | $293.56M | 3.0% | 11% |
| Total | $1.39B | $1.87B | $2.73B | 5.8% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$2.73B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Powder | $1.59B | 4.7% | 58% |
| Bowel Preparation Kit | $1.15B | 7.4% | 42% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on PEG 3350 Market covering market dynamics, competitive landscape, and strategic outlook.
The PEG 3350 Market market is projected to reach $2.73B by 2030, growing at 5.8% CAGR. The Powder segment holds the largest share.
The rising prevalence of colon cancer in India and other developing nations is one of the major factors driving the growth of the global PEG 3350 market. Likewise, the rising number of strategic initiatives is further fueling the growth of the global market during the review period. However, side effects associated with PEG 3500 are anticipated to hamper the growth of the global market. Nevertheless, market expansion in developing regions is expected to create lucrative opportunities for the players operating in the global PEG 3350 market.
The prevalence of colon cancer is increasing across India and other developing nations. In countries such as India, China, and Japan cases of colon cancer is increasing at a high rate. For instance, according to the article published by, lancet regional health Southeast Asia, colorectal cancer is the 7th most common cancer in India with 65,358 new cases in 2021. The incidence of colon cancer has been increasing worldwide and is currently 19.5 per 100,000 population globally and 15.2 per 100,000 population in India. Similarly, the changing lifestyles that include consumption of calorie-rich and low fibre diet, excessive use of red meat and processed foods, and physical inactivity. Also, the age-sex-adjusted rates of colon cancer in India have also raised by 20.6%, with a sharp increase in adults aged under 50 years.
Therefore, the rising number of colon cancers is likely to increase the demand for PEG 3350. This cumulative prevalence of colon cancer along with changing lifestyle habits such as rising consumption of alcohol and tobacco products, increasing rates of smoking, and poor dietary habits among the population are expected to drive the PEG 3350 markets during the forecast period.
Developing economies pose an opportunity for the PEG 3350 market as they have a developing R&D sector along with improving healthcare infrastructure, owing to which they are capable of addressing upcoming health challenges. In spite of huge demand, several countries are dependent on imported medicines and other health technologies. Although there is a high disease prevalence rate and requirement for treatment, poor economic conditions lead to the slow growth of the healthcare industry within the developing region.
According to the report published by the Colorectal Cancer in the Arab World, there will be 1.93 million new cases of colon cancer present in Arab counties. Cancer is growing at an alarming pace in Middle East region countries. Similarly, 6,597 cases were registered in Malaysia in 2021. The increasing patient pool offers growth opportunities for manufacturers in the PEG 3350 market to expand their reach in such nations and aid in the growth of the global PEG 3350 market.
Strict PEG 3350 is a group of medications called osmotic laxatives. It usually works by allowing water to be more easily absorbed into the stool. This helps stool pass more easily. Polyethylene glycol 3350 works well and doesn’t usually have serious risks. But side effects of constipation treatments vary depending on the method person chooses and the strength of the medication. The most common side effects include nausea, gas, and bloating. These side effects usually are managed at home. The side effects of oral medications can be more serious. It can even upset the stomach or make patients dizzy and lightheaded. Moreover, oral medication can also cause severe side effects, especially severe diarrhoea. The medication can also increase the irritation of the rectum, sleep disorder, and intense abdominal pain. The safety issues regarding constipation-treated products are expected to hamper the market growth.
The COVID-19 pandemic has caused major destruction in the delivery of healthcare products across the world. It has posed limitations on many patients to access their standard health services such as visits to healthcare professionals, diagnosis, and medications. It has adversely impacted the ability of patients and practitioners to adhere to treatment guidelines. Moreover, the high demand for PEG 3350 and growing awareness about current and new products is also fueling the global PEG 3350 market. For instance, as per the All-India Trade Survey of Prioritised Medicinal Plants, 2019, demand for medicinal plants such as Senna Makki increased by 50%, while the availability declined by 26% during COVID-19. Similarly, the US FDA has also allowed Senna Makki to be used as an over-the-counter drug in case of digestive disorders, such as chronic constipation, hemorrhoids, and irritable bowel syndrome, as it causes laxative action by influencing the transport of water and electrolytes. Hence, the COVID-19 pandemic had a negative impact on the market demand during the initial phase, however, demand normalized as supply chain issues were resolved and restrictions were lifted to some extent.
COVID-19 has led to a disruption in the supply chain of PEG 3350 products. Lockdown policies in different countries have resulted in the closing of product providers and decreasing walk-in customers to prevent the spread of the disease. This led to a significant delay in the supply of the product. Also, during the lockdown period, the PEG 3350 market for online delivery of products has seen a rise, which nullified the negative impact on physical pharmacies to some extent. The leading companies of the PEG 3350 market across the world have taken major steps to properly supply their products to people globally.
The COVID-19 pandemic situation has resulted in many restrictions around the world, still, the players manufacturing PEG 3350 products were able to manage their product stock. Further, governing bodies of respective nations made significant efforts to aid in the proper distribution and supple of healthcare goods. Government and private companies around the world were working together to issue advice for those undergoing constipation treatment during these unprecedented times of COVID-19 around the world. Several steps were taken to get their needed output for the product. Additionally, by increasing the material prices, the companies attempted in maintaining their overall revenue. Hence, companies in the PEG 3350 market are finding out their ways to deal with this pandemic situation.
Profiles of 105 companies operating in the PEG 3350 Market market, including revenue, employee count, and market positioning where available.
Showing 105 of 105 companies
BASF is the world's largest chemical company by sales, built on the Verbund principle of physically and energetically integrated production sites that turn a handful of feedstocks into thousands of products. Since September 2024 it has run under the "Winning Ways" strategy, which splits the portfolio into four core segments (Chemicals, Materials, Industrial Solutions, Nutrition & Care) that stay integrated, and standalone businesses (Agricultural Solutions, Battery Materials, Environmental Catalyst and Metal Solutions, and the now-divested Coatings) that are being monetized or prepared for capital-market options. In 2025 it generated €59.7 billion in sales and €6.6 billion in EBITDA before special items, a cyclical trough. In 2026 it closed the €7.7 billion Coatings transaction, started up its €-multi-billion Zhanjiang Verbund site, raised earnings guidance, and approached Evonik about a takeover. The investment debate is whether structural cost cuts and portfolio proceeds can restore returns above the cost of capital. --- **The company's own description.** BASF describes its purpose with the line "we create chemistry for a sustainable future" (BASF news release boilerplate, 2026) and states its ambition to be the preferred chemical company for enabling customers' green transformation. It reports around 108,000 employees, customers in nearly every sector and almost every country, and sales of around €60 billion in 2025. The portfolio is described as four core segments plus standalone businesses bundled in Surface Technologies and Agricultural Solutions. **Independent characterization.** BASF is best understood as three businesses under one roof: 1. **An integrated commodity and intermediates engine** (Chemicals, the Monomers half of Materials). This is a steam-cracker-to-derivatives chain selling ethylene and propylene derivatives, isocyanates, polyamide precursors and intermediates on spread economics. Earnings are driven by feedstock and energy costs, operating rates and regional supply-demand. It is the most capital-intensive part of the group and the main source of the 2023–2025 earnings decline: Chemicals EBITDA before special items fell from €1,342 million in 2024 to €853 million in 2025 (Factsheet FY2025). 2. **Formulated and performance products** (Performance Materials, Industrial Solutions, Nutrition & Care). These sell on specification and performance to automotive, construction, packaging, consumer goods, pharma and nutrition customers. Margins are steadier but have come under pressure from Asian competition and, in Care Chemicals, from consumer trading-down to private-label products (Factsheet FY2025 commentary). 3. **Standalone franchises** with different industry logic: Agricultural Solutions (crop protection, seeds and traits, digital farming), ECMS (emissions catalysts plus precious-metal trading and recycling) and Battery Materials. Agricultural Solutions is the group's highest-margin segment at 21.7% EBITDA margin before special items in FY2025 and the largest single earnings contributor at €2,081 million. **Revenue model.** Revenue is almost entirely product sales under supply contracts and spot transactions. There is no subscription model of consequence; digital farming (xarvio) and licensing of process technology and catalysts are small. Seeds and traits include royalty and licensing income within Agricultural Solutions, not separately disclosed. Precious-metal trading inflates ECMS sales (€7,978 million in FY2025) with pass-through metal value, which is why BASF quotes group margins both including and excluding metals (12.3% excluding metals in FY2025 per the CFO on the February 27, 2026 call, versus 11.0% reported). **Value chain position.** Upstream to midstream in petrochemicals with captive crackers at Ludwigshafen, Antwerp, Port Arthur (joint venture with TotalEnergies), Nanjing (joint venture with Sinopec) and Zhanjiang; midstream to downstream in engineering plastics, polyurethane systems, dispersions, additives, surfactants and vitamins; branded and channel-driven in agriculture. BASF exited upstream oil and gas operations when Wintershall Dea's E&P business was transferred to Harbour Energy in September 2024. **Customers and end-markets.** BASF serves industrial customers in chemicals and plastics, transportation, construction, consumer goods, agriculture, electronics, energy and resources, and health and nutrition. Intersegment transfers are large (Chemicals transferred €3,432 million internally in FY2025 on €10,055 million of third-party sales), which shows how much of the upstream output feeds BASF's own downstream chains.
Bayer is a German life-science group with three businesses: Crop Science, Pharmaceuticals and Consumer Health. It is the world's largest combined seed, trait and crop-protection supplier, a mid-sized prescription-drug maker, and a top-five self-care company. Fiscal 2025 sales were EUR 45.6 billion. The 2018 purchase of Monsanto brought leading corn and soybean genetics but also glyphosate and PCB litigation, which has consumed well over EUR 10 billion in settlements and produced net losses in 2023, 2024 and 2025. Under CEO Bill Anderson the company has cut management layers, held the dividend at the legal minimum, and concentrated on four priorities: rebuilding the pharma pipeline, containing litigation, reducing debt and improving crop profitability. In 2026 a 7–2 U.S. Supreme Court ruling on federal pre-emption and a proposed USD 7.25 billion class settlement moved the litigation closer to resolution, though the settlement still awaits final court approval. --- **Company's own description.** Bayer describes itself as a global enterprise with core competencies in the life-science fields of health care and nutrition, operating under the mission "Health for all, Hunger for none" (Annual Report 2025; press boilerplate 2026). Bayer AG is a holding company; operations sit in subsidiaries worldwide. In fiscal 2025 the Group had about 88,000 employees, sales of EUR 45.6 billion and R&D expenses of EUR 5.8 billion. **Independent characterisation.** Bayer is best understood as three distinct businesses sharing a balance sheet, a brand and a legal liability. Crop Science (47 percent of FY2025 sales) is an input supplier to farmers. It earns money from proprietary seed and biotech traits, from chemical and biological crop protection, and to a small extent from digital farming subscriptions. Seed and trait revenue carries royalty-like economics: Bayer licenses traits to other seed companies, and two licensing settlements with Corteva lifted results in Q4 2025 and Q1 2026. The business is strongly seasonal, with Northern Hemisphere sales concentrated in the first half and Latin American sales in the second. Pharmaceuticals (39 percent of sales) discovers, develops and sells prescription medicines, concentrated in cardiovascular and renal disease, oncology, women's health and ophthalmology, plus a radiology unit selling contrast agents and injector hardware. Revenue is almost entirely product sales, with some licence income (for example U.S. Xarelto royalties from Johnson & Johnson, and Eylea outside the United States under a collaboration with Regeneron). The division is in the middle of a patent transition: Xarelto and Eylea are declining while Nubeqa and Kerendia are growing quickly. Consumer Health (13 percent of sales) sells non-prescription brands through pharmacies, mass retail and e-commerce. It is a branded consumer-goods model with stable margins and low capital intensity. **Revenue model mix.** Bayer does not disclose a product/service/licensing split. On the evidence of the Annual Report 2025, the large majority of revenue is product sales; licensing income is embedded in Crop Science seed and trait lines and in Pharmaceuticals; subscription revenue (Climate FieldView, radiology software) is immaterial at Group level. An exact percentage split is not publicly disclosed. **Value-chain position.** Bayer is a research-based originator and manufacturer. It owns discovery, development, active-ingredient and finished-product manufacturing, and commercial organisations, and sells through distributors, retailers, wholesalers, hospitals and pharmacies rather than directly to end users in most markets. **Customers and end markets.** Farmers, agricultural retailers and distributors, and seed licensees (Crop Science); wholesalers, hospitals, physicians, pharmacy chains, governments and payers (Pharmaceuticals); pharmacies, supermarkets, drugstores and online retailers (Consumer Health).
Company Headquarters: Quebec, Canada Founded: 2003 Workforce: ~ 1,500 Company Working: Pendopharm manufactures and distributes pharmaceutical products. The Company offers licensing, partnering, developing, and marketing specialty prescription medicines, as well as consumer healthcare products. Pendopharm serves customers in Canada. Moreover, it also offers more than 40 specialty products across multiple therapeutic areas. Pendopharm operates as a subsidiary of Pharmascience Inc. In addition, the company established lasting and fruitful relationships with Canadian healthcare professionals through the development of partnerships and sustained delivery of quality products and value-added service.
Company Headquarters: Mumbai, India Founded: 1975 Workforce: ~ 200-500 Company Working: Sisco Research Laboratories Pvt. Ltd. (SRL), one of India's oldest and most reputable manufacturers and suppliers, manufactures and provides almost 5000 high-quality Laboratory Chemicals and Related Products. The business specialises in culture media, high purity solvents, BioLitTM DNA & Protein Tools for PCR and conventional molecular biology, as well as Molecular Biology Reagents, Biochemicals, Enzymes, Nanopowders, and Carbon Nanotubes. SRL was founded in 1975, and for more than 40 years the company has been producing highly sophisticated, high-quality biochemicals and reagents in India. Around 5000 goods in various grades, product sectors, and conventional packing sizes are produced and marketed by the company. The company also provides these high-tech chemicals in bulk and semi-bulk packs for the broader requirements of R&D and production units of various companies, universities, and research institutes.
Company Headquarters: Florida, US Founded: 2005 Workforce: ~100 Company Working: LGM Pharma is one of the active pharmaceutical ingredient companies that offers API sourcing as well as drug product contract development and manufacturing solutions to the biotechnology, pharmaceutical, and compounding pharmacy industries. It has ISO 9001:2015 certification. The company has an unparalleled network of prequalified cGMP API manufacturers around the globe. It has US-based manufacturing and warehouse facilities and has delivered more than 6,000 APIs to its clients in the last three years.
Coty is a fragrance-led global beauty company and, by its own description, one of the world's largest beauty groups, with FY2026 net revenues of USD 5.81bn split roughly two-thirds Prestige (licensed and owned luxury fragrance, prestige cosmetics and skincare — Burberry, Hugo Boss, Calvin Klein, Chloé, Marc Jacobs, Davidoff, Kylie Cosmetics, Gucci until mid-2027) and one-third Consumer Beauty (mass color cosmetics such as CoverGirl, Rimmel, Max Factor and Sally Hansen; mass fragrance; and Brazilian body care). Its core competitive asset is an end-to-end fragrance platform — licensing, innovation, ~81% in-house manufacturing and global prestige distribution — that has produced blockbuster franchises such as Burberry Goddess. After five years of deleveraging under Sue Nabi, Coty entered 2026 in a reset: revenue and margins are declining, the Gucci licence exits a year early, mass color and Brazil are under strategic review, and new interim leadership is executing a "Coty.Curated" focus-and-simplify framework with leverage of 3.4x. --- **Company's own description (paraphrased from FY2026 10-K, Item 1).** Coty describes itself as one of the world's largest beauty companies with an iconic brand portfolio across fragrance, color cosmetics, and skin and body care. It states that it is focused on leveraging its leadership position and capabilities in global fragrances to fuel expansion, strengthening its presence in a limited number of structurally profitable and growing categories, and prioritising growth channels such as e-commerce and Travel Retail. Under the Coty.Curated framework it emphasises fewer, bigger initiatives, marketing sufficiency, supply reliability, consumer advocacy, more productive innovation and portfolio choices, a return to market-share growth, and AI-powered, data-driven operations. It is also evaluating its central organisation, manufacturing and asset base to resize after the Gucci exit. **What the company does.** Coty designs, manufactures (≈81% in-house, ≈19% via third-party manufacturers in FY2026), markets and distributes beauty products. The essential oils in its fragrances are generally sourced from specialist fragrance houses; Coty owns the brand development, juice selection/briefing, bottle and packaging design, filling and assembly, marketing and commercial execution. Principal raw materials are essential oils, alcohols and specialty chemicals (10-K FY2026). **Business model and revenue model.** **Value-chain position.** Coty sits between ingredient suppliers (fragrance houses, alcohol and packaging suppliers) and retailers. Its economic moat lies in (i) licence portfolio scale in prestige fragrance, (ii) innovation and launch capability (brief-to-shelf), and (iii) owned manufacturing in the U.S., Europe and Brazil. It is structurally exposed to licensors (who own the trademarks) and to concentrated retailers (Sephora, Ulta, Douglas, Walmart, drug chains, travel-retail operators). **End markets.** Prestige fragrance (core), prestige cosmetics (Kylie Cosmetics, Marc Jacobs Beauty, Gucci Beauty until FY2027), prestige skincare (Lancaster, philosophy), mass color cosmetics, mass fragrance and mists, mass skin & body care (concentrated in Brazil). **Independent characterisation.** Coty is effectively two businesses with very different economics: a high-quality, licence-dependent prestige fragrance franchise generating ~20% adjusted EBITDA margins (Prestige FY2026 adjusted EBITDA margin 20.5% per Q4 FY2026 call), and a structurally challenged mass color cosmetics/Brazil business whose segment adjusted EBITDA margin collapsed to the low single digits in FY2026 (derived). The 2025–2026 strategic actions (Wella exit, Gucci monetisation, Consumer Beauty review) are converting Coty into a narrower fragrance pure-play with lower leverage but higher licence concentration.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Mn)
